Cancer drug resistance: an evolving paradigm
C Holohan, S Van Schaeybroeck, DB Longley… - Nature Reviews …, 2013 - nature.com
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing
current cancer research. The mechanisms of resistance to'classical'cytotoxic …
current cancer research. The mechanisms of resistance to'classical'cytotoxic …
[HTML][HTML] Deconstructing the molecular portraits of breast cancer
Breast cancer is a heterogeneous disease in terms of histology, therapeutic response,
dissemination patterns to distant sites, and patient outcomes. Global gene expression …
dissemination patterns to distant sites, and patient outcomes. Global gene expression …
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses
Tumor-infiltrating immune cells can promote chemoresistance and metastatic spread in
aggressive tumors. Consequently, the type and quality of immune responses present in the …
aggressive tumors. Consequently, the type and quality of immune responses present in the …
[HTML][HTML] Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer
E Kudelova, M Smolar, V Holubekova… - International Journal of …, 2022 - mdpi.com
Heterogeneity of triple-negative breast cancer is well known at clinical, histopathological,
and molecular levels. Genomic instability and greater mutation rates, which may result in the …
and molecular levels. Genomic instability and greater mutation rates, which may result in the …
Histological, molecular and functional subtypes of breast cancers
Increased understanding of the molecular heterogeneity that is intrinsic to the various
subtypes of breast cancer will likely shape the future of breast cancer diagnosis, prognosis …
subtypes of breast cancer will likely shape the future of breast cancer diagnosis, prognosis …
[HTML][HTML] Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Introduction In breast cancer, gene expression analyses have defined five tumor subtypes
(luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has …
(luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has …
Cancer stem cells, cancer cell plasticity and radiation therapy
E Vlashi, F Pajonk - Seminars in cancer biology, 2015 - Elsevier
Since the first prospective identification of cancer stem cells in solid cancers the cancer stem
cell hypothesis has reemerged as a research topic of increasing interest. It postulates that …
cell hypothesis has reemerged as a research topic of increasing interest. It postulates that …
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype
Background and Aim The study of CD44/CD24 and ALDH1 expression is the most accurate
method to identify cancer stem cells (CSC) from breast cancer populations. However, the …
method to identify cancer stem cells (CSC) from breast cancer populations. However, the …
Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis
P Marcato, CA Dean, D Pan, R Araslanova, M Gillis… - Stem …, 2011 - academic.oup.com
Cancer stem cells (CSCs) are proposed to initiate cancer and propagate metastasis. Breast
CSCs identified by aldehyde dehydrogenase (ALDH) activity are highly tumorigenic in …
CSCs identified by aldehyde dehydrogenase (ALDH) activity are highly tumorigenic in …
The developing cancer stem-cell model: clinical challenges and opportunities
L Vermeulen, FS e Melo, DJ Richel… - The lancet oncology, 2012 - thelancet.com
During the past decade, a stem-cell-like subset of cancer cells has been identified in many
malignancies. These cells, referred to as cancer stem cells (CSCs), are of particular interest …
malignancies. These cells, referred to as cancer stem cells (CSCs), are of particular interest …